Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 448 across all filing types
Latest filing 2025-05-10 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a short notification addressed to stock exchanges under Regulation 30 read with Schedule III of SEBI Listing Regulations. It informs about a third party (Allecra Therapeutics GmbH) filing for insolvency, which is relevant to Orchid Pharma Limited due to an out-licensing agreement. The document is brief (1266 characters), does not contain financial statements or detailed financial data, and serves as a regulatory update to the exchanges. It is not a full report, earnings release, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-05-10 English
Updates
Regulatory Filings
2025-05-03 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-04-11 English
Agreements
Regulatory Filings Classification · 95% confidence The document is an official intimation under Regulation 30 of the SEBI Listing Regulations regarding the entering into a Joint Memo of Compromise with DBS Bank India Limited. It details the settlement of a dispute related to lease rentals and includes specifics as required by SEBI regulations. The document is a regulatory announcement about a material event affecting the company, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather compliance disclosure information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-09 English
Action(s) taken or orders passed
Regulatory Filings Classification · 95% confidence The document is a letter from Orchid Pharma Limited addressing cautionary letters/emails received from stock exchanges (BSE and NSE) regarding delayed disclosures of investor/analyst meeting schedules. It references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes annexures with details of the cautionary letters and emails. The content is regulatory in nature, reporting on compliance issues and corrective measures, but does not contain financial statements, audit results, or detailed financial data. It is not a report itself but a regulatory communication about compliance and cautionary notices. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2025-03-29 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is an official notice from Orchid Pharma Limited regarding the closure of the trading window for insiders ahead of the announcement of the audited financial results for the quarter IV and financial year ending March 31, 2025. It references regulatory compliance with SEBI regulations on insider trading and informs about the trading restrictions during the period before and after the financial results are declared. The document does not contain any financial data or the results themselves, nor does it announce the results. It is a regulatory announcement related to trading restrictions and compliance, not a financial report or earnings release. The document length is short (2957 characters) and it serves as an intimation or notice rather than a report. Therefore, it fits best under Regulatory Filings (RNS).
2025-03-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.